Initial clinical experience with the radiosensitizing nitroimidazole Ro 07-0582

Area of Science:

• Oncology
• Pharmacology
• Radiation Oncology

Background:

• The 2-nitroimidazole derivative Ro 07-0582 is an experimental radiosensitizer effective against hypoxic cells.
• Clinical data on Ro 07-0582's efficacy and safety are limited.
• Hypoxic tumor cells pose a significant challenge in cancer treatment, requiring effective radiosensitizers.

Purpose of the Study:

• To evaluate the side effects of Ro 07-0582 in a clinical setting.
• To determine the dose-limiting toxicity of Ro 07-0582.
• To assess the potential therapeutic benefit of Ro 07-0582 in patients with brain and extracerebral tumors.

Main Methods:

• Observational study of 12 patients (9 with brain tumors, 3 with extracerebral tumors) treated with Ro 07-0582.
• Detailed recording and analysis of all observed side effects.
• Correlation of side effects with the total administered dose of Ro 07-0582.

Main Results:

• Sensoric polyneuropathy occurred in 8 out of 12 patients, strongly dose-dependent, with onset around 22-26 grams.
• A severe organic psychosyndrome was observed in one patient, possibly drug-related.
• All observed side effects, including polyneuropathy and psychosyndrome, were reversible within 4 weeks after drug cessation.
• A critical dose limit of 29 grams was suggested for Ro 07-0582 administration.

Conclusions:

• Ro 07-0582 is a potent radiosensitizer with manageable and reversible side effects at doses below 29 grams.
• The recommended fractionation (6 fractions of 60-80 mg/kg) aims to achieve a radiosensitizing enhancement ratio of 1.5.
• Further clinical studies are warranted to confirm the safety and efficacy of Ro 07-0582 in hypoxic tumor treatment.